Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987294 | 0.85 | MAPK1 (0.53) | KDM4EALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL3242105 | 0.81 | SCD (0.46) | ALDH1A1HPGDSMN1; SMN2KDREIF2AK2 | |
| SCHEMBL1992948 | 0.79 | SMN1; SMN2 (0.49) | KDM4EALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL1967150 | 0.79 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL1395381 | 0.71 | ALDH1A1 (0.58) | KDM4EALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL1393716 | 0.71 | SMN1; SMN2 (0.58) | KDM4EALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL14629954 | 0.70 | ALDH1A1 (0.70) | KDM4EALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL28884696 | 0.65 | GRM5 (0.40) | — | |
| SCHEMBL29934042 | 0.65 | GRM5 (0.40) | — | |
| SCHEMBL1238494 | 0.65 | KDM4E (0.51) | KDM4EALDH1A1HPGDMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2334666-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Canada Inc. (CA) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | KDM4E 2485/4885ALDH1A1 518/4885HPGD 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.